IRadimed Q1 revenue rises 13% on new product launch

IRADIMED

01/05/2026 13:38

Overview

MRI-compatible device maker's Q1 revenue rose 13% yr/yr to $22.0 mln

Adjusted EPS for Q1 rose 17% yr/yr to $0.49

Company says Q1 growth driven by launch of next-gen 3870 MRI IV pump

Outlook

Company expects Q2 2026 revenue of $20 mln to $21 mln

Company sees Q2 2026 GAAP diluted EPS of $0.40 to $0.44

Company reaffirms 2026 revenue guidance of $91 mln to $96 mln

Result Drivers

NEW PRODUCT LAUNCH - Co said Q1 growth was driven by commercial launch of next-generation 3870 MRI-compatible IV infusion pump, with strong early order activity and larger order sizes

EXPENSE MANAGEMENT - Co said disciplined expense management contributed to improved operating income

Company press release: ID:nGNX4XfKVg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$22 mln
$21.32 mln (2 Analysts)
Q1 Adjusted EPS
Beat
$0.49
$0.45 (2 Analysts)
Q1 EPS
$0.45


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for IRadimed Corp is $120.00, about 43.8% above its April 30 closing price of $83.44

The stock recently traded at 39 times the next 12-month earnings vs. a P/E of 46 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)